OpenAlex records 406 works, 22,604 citations, and an h-index of 77 for Susan Morgello (Icahn School of Medicine at Mount Sinai), with peak productivity in 2012β2014 (27, 26, and 29 works) and citation peaks tied to the CHARTER HAND papers (2,353 and 1,533 citations for the 2010 Neurology and J NeuroVirology articles) . Her early independent work (GLUT1 astrocyte localization, 1995; R29-NS31865) shows basic neuropathology origins, while recent years show a shift toward mechanistic vascular biology .
The 2019 ATV paper is her strongest reviewed work (quality 9/10, novelty 9/10): a novel nonreplicating-HIV-transcript mouse crossed onto ApoEβ/β, plus bone-marrow transplantation to prove hematopoietic causation, plus a 153-person HIV cohort and autopsy validation . Limitations are honestly flagged: nonreplicating model may not recapitulate full HIV biology, mouse sample sizes incompletely reported, human data cross-sectional, and autopsy plaques from severe disease only.
Note: control-chimera value inferred from reported comparison design; exact control SD not independently specified in extract.
The 2013 autonomic study (N=102, single clinic) rigorously quantified CASSβDSP correlation (r=0.33, p=0.001) and controlled for anticholinergic burden and polypharmacy, but is limited by cross-sectional single-clinic sampling and no formal CNS neuropsychology . The 2004 J Virol phylogenetic work on CNS compartmentalization of drug-resistance mutations was conceptually novel (novelty 8/10) but reproducibility scored lower (5/10), reflecting retrospective tissue-bank sampling and incomplete ART records .
The 1994 Muscle & Nerve CMV demyelinative polyneuropathy case report (single 47-year-old patient) demonstrated rigorous multimodal characterization β electrophysiology, histology, EM β and pragmatically suggested early empirical anti-CMV therapy, but generalizability is inherently limited (generality 3/10) .
What would change conclusions: Replication of caspase-1 findings in replicating-virus models or prospective longitudinal human cohorts; larger CNS phylogenetic sampling with known ART histories; multi-site autonomic validation cohorts.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.